First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Enriqueta Felip1 · Victor Moreno2 · Daniel Morgensztern3 · Giuseppe Curigliano4 · Piotr Rutkowski5 · José Manuel Trigo6 · Aitana Calvo7 · Dariusz Kowsalski5 · Diego Cortinovis8 · Ruth Plummer9 · Michele Maio10 · Paolo A. Ascierto11 · Vladimir I. Vladimirov12 · Andres Cervantes13 · Enrique Zudaire14 · Anasuya Hazra14 · Huybrecht T’jollyn15 · Nibedita Bandyopadhyay16 · James G. Greger14 · Edward Attiyeh14 · Hong Xie14 · Emiliano Calvo17

Received: 21 September 2021 / Accepted: 16 February 2022 / Published online: 17 March 2022 © The Author(s) 2022

Abstract
Purpose To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the phase 1/2 LUC1001 study.
Methods In phase 1, patients with advanced solid tumors received intravenous cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W. In phase 2, patients with melanoma, non-small-cell lung cancer (NSCLC), and microsatellite instability–high (MSI-H)/DNA mismatch repair-deficient colorectal cancer (CRC) received cetrelimab 240 mg Q2W. Response was assessed Q8W until Week 24 and Q12W thereafter.
Results In phase 1, 58 patients received cetrelimab. Two dose-limiting toxicities were reported and two recommended phase 2 doses (RP2D) were defined (240 mg Q2W or 480 mg Q4W). After a first dose, mean maximum serum concentrations ($C_{\text{max}}$) ranged from 24.7 to 227.0 µg/mL; median time to $C_{\text{max}}$ ranged from 2.0 to 3.2 h. Pharmacodynamic effect was maintained throughout the dosing period across doses. In phase 2, 146 patients received cetrelimab 240 mg Q2W. Grade ≥ 3 adverse events (AEs) occurred in 53.9% of patients. Immune-related AEs (any grade) occurred in 35.3% of patients (grade ≥ 3 in 6.9%). Overall response rate was 18.6% across tumor types, 34.3% in NSCLC, 52.6% in programmed death ligand 1–high (≥ 50% by immunohistochemistry) NSCLC, 28.0% in melanoma, and 23.8% in centrally confirmed MSI-H CRC.
Conclusions The RP2D for cetrelimab was established. Pharmacokinetic/pharmacodynamic characteristics, safety profile, and clinical activity of cetrelimab in immune-sensitive advanced cancers were consistent with known PD-1 inhibitors.
Trial registrations NCT02908906 at ClinicalTrials.gov, September 21, 2016; EudraCT 2016–002,017-22 at clinicaltrialsregister.eu, Jan 11, 2017.

Keywords Monoclonal antibody PD-1 inhibitor efficacy · Non-small-cell lung cancer · Melanoma · Colorectal cancer · Microsatellite instability–high · Pharmacokinetics/pharmacodynamics

Introduction
The development of immune checkpoint inhibitors led to improved outcomes and expanded opportunities for targeted combination therapies in numerous tumor types [1].

The programmed cell death protein-1 (PD-1) is an immune checkpoint receptor that regulates adaptive T cell immunity. PD-1 is expressed on activated CD4+ and CD8+ T cells and suppresses T cell function when bound to its ligands, programmed death ligand 1 (PD-L1) and 2 (PD-L2). In the tumor microenvironment, PD-1 activity can suppress tumor immunosurveillance and development of adaptive immune responses [1, 2]. Hence, blocking PD-1 receptor–ligand interactions can enhance antitumor immune responses to tumor cells.
Monoclonal antibody PD-1 inhibitors such as pembrolizumab [3, 4], nivolumab [5, 6], and cemiplimab [7, 8] have been approved by the US Food and Drug Administration and the European Medicines Agency based on durable responses in immune-sensitive cancers. Other PD-1 inhibitors have been approved for various cancer treatment indications in different geographic regions.

Several biomarkers have been identified to be predictive of response to PD-1 antagonists. Nivolumab and pembrolizumab have demonstrated higher response rates in solid tumors in which > 1% of cells are PD-L1 + by immunohistochemistry (IHC) compared with tumors with < 1% PD-L1 positivity [9–11]. Tumor cells deficient in mismatched DNA repair systems (dMMR) are responsive to these agents and microsatellite instability (MSI) has proven to be a marker for dMMR [12–15].

Cetrelimab is a fully human immunoglobulin G4 monoclonal antibody inhibitor of PD-1. The in vitro binding affinity to the human PD-1 extracellular domain for cetrelimab is \( K_D = 1.72 \text{ nM} \) [16] compared with pembrolizumab at \( K_D = 29 \text{ pM} \) [17, 18] and nivolumab at \( K_D = 3.06 \text{ nM} \) [18, 19]. Like nivolumab and pembrolizumab, cetrelimab completely inhibits binding of PD-1 to PD-L1 and PD-L2. All three PD-1 inhibitors have demonstrated dose-dependent induction of interferon (IFN)-\( \gamma \), tumor necrosis factor-\( \alpha \), and interleukin (IL)-4 upon cytomegalovirus (CMV) stimulation of CMV-reactive T cells from peripheral blood of CMV-responsive donors or CD4\(^+\) T cells that were activated by stimulation with allogeneic, major histocompatibility complex–mismatched, dendritic cells [18, 20]. Like nivolumab [20] and pembrolizumab [18], cetrelimab achieved tumor growth inhibition of MC38 tumors implanted on human PD-1 knock-in mice (companion paper by DeAngelis et al. in this issue of Cancer Chemotherapy and Pharmacology).

The first-in-human phase 1/2 LUC1001 study was designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of cetrelimab in patients with advanced solid tumors.

### Materials and methods

#### Study design

LUC1001 (NCT02908906, EudraCT 2016–002,017–22) was an open-label, multicenter phase 1/2 study of cetrelimab (Fig. 1) initiated in Nov 2016. LUC1001 was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Standards and the Declaration of Helsinki. The protocol was approved by institutional and ethics committees. All patients provided written informed consent.

#### Patients

All patients enrolled in LUC1001 were required to be aged ≥ 18 years, with metastatic or unresectable solid tumors, and had progressed on or been deemed ineligible for standard antitumor therapy. Patients were required to have Eastern Cooperative Oncology Group performance status ≤ 1 and to have had no prior treatment with PD-1/ PD-L1 inhibitors.

Patients with any solid tumor except lymphoma were eligible to enroll in the phase 1 part of LUC1001. Tissue sample collection for PD-L1 testing was optional in phase...
but mandatory in phase 2. The phase 2 part of LUC1001 was initially designed to enroll patients with histologically or cytologically confirmed stage III or IV PD-L1+ [≥ 1% PD-L1+ on tumor cells assessed centrally with the 22C3 antibody (Dako Omnis; Agilent, Santa Clara, CA) or local testing] non-small-cell lung cancer (NSCLC), melanoma, or colorectal cancer (CRC), as well as renal cell carcinoma, bladder cancer, small-cell lung cancer (SCLC), and gastric/esophageal cancer. The protocol was amended to limit phase 2 recruitment to PD-L1-high (≥ 50% PD-L1+ on tumor cells) NSCLC, melanoma, and MSI-high (MSI-H)/dMMR CRC determined by local or central testing. MSI-H status was centrally confirmed retrospectively using the Promega fluorescent PCR-based MSI Analysis System v1.2 (Promega Corporation, Madison, WI). For both PD-L1 status in NSCLC and MSI-H status in CRC, only central testing data were used in this analysis.

**Study treatments**

Phase 1 included five dose-escalation cohorts and three pharmacokinetics/pharmacodynamics cohorts; patients received intravenous (IV) 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W doses of cetrelimab (Fig. 1). Additionally, feasibility of subcutaneous (SC) administration of cetrelimab was, and continues to be, explored. SC injection was administered by slow manual push. All patients in phase 1 and 2 received a frozen liquid formulation except pharmacokinetics/pharmacodynamics Cohort 2a, in which 12 patients received the lyophilized formulation at 480 mg Q4W, and pharmacokinetics/pharmacodynamics Cohort 3 (SC cohort), in which six patients received the lyophilized formulation by SC injection. The first IV infusion was delivered over 60 min. If the 60-min infusion was well tolerated, subsequent infusions could be delivered over 30 min.

Because of limited information due to the small sample size, pharmacokinetic data in the SC cohort are not reported here; these patients were included with the appropriate tumor-specific groups in efficacy assessments and with the IV 480 mg Q4W dose group in safety assessments.

**Dose escalation**

Decisions about dose escalation were based on the rate of dose-limiting toxicities (DLTs) observed during the first 28 days on treatment. DLTs were defined as toxicities of grade 5, grade 4 (including neutropenia lasting ≥ 7 days and thrombocytopenia of any duration), or grade ≥ 3 [with the exception of asthenia, fever, constipation, fatigue that improves in ≤ 7 days, nausea lasting for ≤ 7 days with standard of care, vomiting or diarrhea lasting ≤ 3 days with standard care, tumor flare (local pain, irritation, or rash at known or suspected tumor sites) that improves in ≤ 7 days, aspartate aminotransferase/alanine aminotransferase (AST/ALT) elevation lasting < 7 days, laboratory abnormalities not requiring hospitalization and deemed not clinically significant by the investigator, and thrombocytopenia without clinically significant bleeding]. ALT/AST elevations meeting Hy’s law criteria and immune-related toxicities requiring treatment in excess of corticosteroids were included in the DLT definition.

**Cohort expansion**

The clinical activity and safety of cetrelimab at the chosen RP2D in three tumor-specific groups (NSCLC, melanoma, and MSI-H/dMMR CRC) were assessed in phase 2 to confirm the selected doses.

**Study endpoints**

The primary endpoints were the safety and tolerability, and overall response rate (ORR) of cetrelimab. Secondary objectives included assessment of pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy by the investigator, including the clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and duration of response (DOR). Selected biomarkers were examined for potential association with pharmacodynamic modulation of cetrelimab.

**Safety assessments**

Safety assessments included the frequency and severity of treatment-emergent adverse events (TEAEs) and immune-related adverse events (irAEs), infusion-related reactions (IRRs), vital sign measurements, clinical laboratory values, and electrocardiograms. The severity of AE was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v4. irAEs and IRRs were designated by the investigators. Investigators were instructed to consider all events of an inflammatory nature immune related in the absence of a clear alternative etiology.

**Pharmacokinetics and receptor occupancy**

Blood samples were collected for pharmacokinetic analyses on the day of dosing both pre-infusion (within 2 h) and at the end of infusion (EOI) for the first ten doses in cohorts receiving Q2W dosing. After Dose 1 and Dose 9, additional blood samples were collected at 2 h (EOI + 2 h) and 6 h (EOI + 6 h) post infusion as well as on Days 2, 4, and 8 in the cohorts receiving Q2W dosing. After Dose 1 and Dose 5 in cohorts receiving Q4W dosing, additional samples were collected at EOI + 2 h and EOI + 6 h post infusion as well as on Days 2, 4, 8, 15, and 22. In the SC cohort, blood samples
were collected for the sentinel SC dose at the following time points: pre-injection (within 2 h), post injection (PI), PI + 2 h, and PI + 6 h, as well as on Days 2, 4, 8, 15, 22, 29, and 36. Samples were also collected at the end-of-treatment (EOT) visit (≤ 30 days after the last dose) and first survival follow-up visit (~ 12 weeks after the last dose).

Serum cetrelimab concentrations were measured using a validated electrochemiluminescence immunoassay method. As previously mentioned, two drug product formulations were tested at the 480 mg Q4W dose.

Individual pharmacokinetic parameters were calculated using noncompartmental analysis (NCA) and descriptive statistics were provided. A two-compartmental disposition population pharmacokinetic (popPK) model with first-order elimination and zero-order IV infusion rate, parameterized in terms of clearance (CL), volume of central compartment (V1), intercompartmental CL (Q), and volume of peripheral compartment (V2), was used to describe the pharmacokinetics of cetrelimab from both phase 1 and phase 2 parts of LUC1001. Interindividual variability (IIV) was implemented on CL, V1, and V2, with random-effects correlation estimated between CL and V1. IIV was also included on residual error to allow for patient-level variations in residual error. Additionally, popPK modeling and simulations were performed using data from all dose cohorts to explore multiple phase 2 dosing regimens targeting comparable pharmacokinetic profiles and exposures similar to nivolumab and pembrolizumab.

Fresh whole blood was collected from all patients in phase 1 and from the first 40 patients in phase 2 for evaluation of PD-1 receptor occupancy (RO) on circulating CD3+ T cells by flow cytometry analysis. During phase 1, Dose 1 samples were taken on Day 1 before infusion and 2 h after EOI and on Day 8; Dose 2 samples were taken on Day 1 before infusion and at EOI. Samples for Dose 3 were taken on Day 1 before infusion, and for Dose 9 on Day 1 before infusion and at EOI. Dose 10 samples were drawn on Day 1 at EOI and at EOT. During phase 2, blood samples were taken before infusion on Dose 1 and Dose 5.

**Pharmacodynamics and biomarkers**

Ex vivo staphylococcal enterotoxin B (SEB) stimulation of IL-2 production by peripheral blood mononuclear cells was conducted to evaluate cetrelimab pharmacodynamic modulation [21]. Briefly, whole blood samples were diluted 1:10 with RPMI 1640 medium (Catalog #111,875,093, Thermo Fisher Scientific, Waltham, MA) followed by a 4-day incubation with 100 ng/mL of SEB and 10 µg/mL of cetrelimab or isotype control. The ratio of IL-2 expression levels between the isotype and cetrelimab ex vivo-treated blood samples was then calculated to assess the degree of pharmacodynamic modulation, with a ratio of 1 indicating maximum T cell activation.

Serum levels of IFN-γ-inducible protein 10 (IP10) and IL-2 receptor alpha chain (IL2Ra) were measured by Meso Scale Discovery (MSD) for all patients with one pretreatment and at least one post-treatment sample collection.

**Immunogenicity**

Serum samples were screened for anti-drug antibodies binding to cetrelimab and the titer of confirmed positive samples was reported.

**Efficacy assessments**

Tumor response was assessed by the investigators per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 [22] every 8 weeks (± 2 weeks) until Week 24, after which assessments were made every 12 weeks (± 2 weeks). Patients were allowed to continue treatment with study drug beyond initial radiologic tumor progression determined on the basis of the RECIST criteria. This allowance took into account the observation that some patients can have a transient tumor flare (i.e., pseudo-progression) in the first few months after the start of immunotherapy but can develop subsequent disease response. Patients were advised to continue study treatment at the discretion of the treating physician while waiting for confirmation of disease progression if they were clinically stable as defined by the following criteria: (1) absence of clinical signs and symptoms indicating disease progression; (2) clinical disease progression not requiring immediate therapeutic intervention; (3) no decline in Eastern Cooperative Oncology Group performance status; and (4) absence of progressive tumor at critical anatomical sites (e.g., cord compression) requiring urgent alternative medical intervention. Patients who were deemed clinically unstable could discontinue study treatment prior to repeat imaging for confirmation of progressive disease.

ORR was defined as the percentage of patients with complete response (CR) + partial response (PR). CBR was defined as the percentage of patients with CR + PR + stable disease lasting ≥ 24 weeks [23]. PFS was defined as the time from first dose of cetrelimab to progressive disease or death due to any cause. OS was defined as the time from first dose of cetrelimab to death due to any cause. DOR was defined as the time from initial response of CR or PR to progressive disease or death due to underlying disease.

**Statistical analysis**

Dose escalation and recommended phase 2 dose identification were guided using a modified continual reassessment method, which was based on the probability
of dose-limiting toxicities by a two-parameter Bayesian logistic regression model and escalation with overdose control principle. The sample size estimation of 180 patients for the overall study population in the dose expansion part of this study was based on the ability to detect a 79.0% success rate if the true ORR is 15.0% and 15.7% if the true ORR is 10.0% by Bayesian power, or a 43.2% success rate if the true ORR is 15.0% and 1.3% if the true ORR is 10% by Bayesian double criteria. The all-treated population, defined as patients who received ≥ 1 dose of cetrelimab, was the basis for both safety and efficacy analyses. Subpopulations of patients with NSCLC, melanoma, and CRC were analyzed individually. The ORR is presented with 2-sided 95% exact Clopper–Pearson confidence intervals (CIs). Time-to-event endpoints and corresponding 95% CIs were estimated using Kaplan–Meier methodology.

**Results**

**Patients**

At clinical data cutoff on Jul 1, 2019, the all-treated population comprised 204 patients (58 in phase 1 and 146 in phase 2). Median age was 60.0 years (range, 23.0–86.0 years) and 56.9% were male (Table 1). The majority of patients (70.1%) had previously received ≥ 2 regimens.

**RP2D determination**

Cetrelimab 240 mg Q2W and 480 mg Q4W resulted in the same total dose, while demonstrating sufficient pharmacokinetics/pharmacodynamics coverage to ensure RO saturation throughout the dosing interval. Therefore, the RP2D for cetrelimab may be administered as either 240 mg Q2W or 480 mg Q4W; 240 mg Q2W was selected as the RP2D for the phase 2 part of the study.

---

**Table 1** Demographics and disease characteristics at baseline (all-treated population)

|                      | NSCLC n = 35 | MEL n = 50 | BC n = 4 | RCC n = 2 | SCLC n = 12 | MSI-H/ dMMR CRC n = 48 | Gastric/ esophageal n = 16 | Othera n = 37 | Total N = 204 |
|----------------------|--------------|------------|---------|-----------|-------------|------------------------|-----------------------------|---------------|--------------|
| **Median age, years** |              |            |         |           |             |                        |                             |               |              |
| (range)              | 64.0 (47.0– | 60.5 (23.0– | 64.0 (56.0– | 71.0 (66.0– | 63.0 (46.0– | 59.5 (29.0– | 62.0 (44.0– | 53.0 (27.0– | 60.0 (23.0– |
|                      | 79.0)       | 86.0)      | 79.0)   | 76.0)     | 80.0)       | 81.0)      | 82.0)        | 80.0)        | 86.0)       |
| **Sex, n (%)**       |              |            |         |           |             |                        |                             |               |              |
| Male                 | 29 (82.9)    | 29 (58.0)  | 3 (75.0) | 1 (50.0)  | 8 (66.7)    | 20 (41.7)  | 10 (62.5)   | 16 (43.2)  | 116 (56.9)  |
| Female               | 6 (17.1)     | 21 (42.0)  | 1 (25.0) | 1 (50.0)  | 4 (33.3)    | 28 (58.3)  | 6 (37.5)    | 21 (56.8)  | 88 (43.1)   |
| **ECOG PS, n (%)**   |              |            |         |           |             |                        |                             |               |              |
| 0                    | 13 (37.1)    | 29 (58.0)  | 2 (50.0) | 0 (0)     | 3 (25.0)    | 27 (56.3)  | 8 (50.0)    | 20 (54.1)  | 102 (50.0)  |
| 1                    | 22 (62.9)    | 21 (42.0)  | 2 (50.0) | 2 (100.0) | 9 (75.0)    | 21 (43.8)  | 8 (50.0)    | 17 (45.9)  | 102 (50.0)  |
| **Previous cancer therapy** |         |            |         |           |             |                        |                             |               |              |
| Surgery/ procedure   | 20 (57.1)    | 49 (98.0)  | 4 (100.0)| 1 (50.0)  | 3 (25.0)    | 48 (100.0) | 11 (68.8)  | 36 (97.3)  | 172 (84.3)  |
| Radiotherapy         | 19 (54.3)    | 20 (40.0)  | 0       | 1 (50.0)  | 11 (91.7)   | 14 (29.2)  | 7 (43.8)    | 22 (59.5)  | 94 (46.1)   |
| Systemic therapy     | 35 (100.0)   | 37 (74.0)  | 4 (100.0)| 2 (100.0) | 12 (100.0)  | 48 (100.0) | 16 (100.0) | 37 (100.0) | 191 (93.6)  |
| **Number of prior lines of regimens, n (%)** |         |            |         |           |             |                        |                             |               |              |
| 0                    | 0 (0)        | 0 (0)      | 0 (0)   | 0 (0)     | 0 (0)       | 0 (0)      | 0 (0)       | 0 (0)      | 13 (6.4)     |
| 1                    | 18 (51.4)    | 12 (24.0)  | 1 (25.0)| 1 (50.0)  | 6 (50.0)    | 2 (4.2)    | 3 (18.8)    | 5 (13.5)   | 48 (23.5)    |
| 2                    | 12 (34.3)    | 15 (30.0)  | 2 (50.0)| 0 (0)     | 4 (33.3)    | 19 (39.6)  | 6 (37.5)    | 8 (21.6)   | 66 (32.4)    |
| ≥ 3                  | 5 (14.3)     | 10 (20.0)  | 1 (25.0)| 1 (50.0)  | 2 (16.7)    | 27 (56.3)  | 7 (43.8)    | 24 (64.9)  | 77 (37.7)    |

BC bladder cancer, CRC colorectal cancer, dMMR DNA mismatch repair deficient, ECOG PS Eastern Cooperative Oncology Group performance status, MEL melanoma, MSI-H microsatellite instability–high, NSCLC non-small-cell lung cancer, RCC renal cell carcinoma, SCLC small-cell lung cancer

aAny other type of advanced or refractory solid tumor malignancy, except lymphoma, that was metastatic or unresectable (e.g., breast cancer, prostate cancer, or pancreatic adenocarcinoma)
Safety

During the phase 1 dose escalation, two DLTs were reported. Both events were considered serious and possibly treatment related. One patient with NSCLC receiving 240 mg Q2W experienced a DLT of grade 3 pleural effusion that resulted in treatment interruption. This patient received seven additional cetrelimab doses after treatment interruption before cetrelimab treatment was discontinued due to disease progression. A second patient with metastatic thymoma receiving 800 mg Q2W experienced a DLT of grade 5 myasthenia gravis, 16 days after receiving Dose 1. Prior treatment for thymoma included four lines of chemotherapy or investigational compounds, radiation for phrenic nerves and pericardial infiltration, and extensive surgical procedures of hemidiaphragm and ipsilateral pericardium excision, left hemithorax pleurectomy, left thoracotomy, myoplasty, pericardial and diaphragmatic replacement, prosthesis placement, tumor resection (thymoma), and posterolateral thoracotomy. The symptom for myasthenia gravis was grade 4 dyspnea and antiacetylcholine receptor antibody was positive. The patient received methylprednisolone 60 mg (1 mg/kg) twice daily and ipratropium bromide, along with noninvasive ventilation; however, diaphragmatic sequelae from multiple chest surgeries limited supportive respiratory therapy options.

The most frequently reported TEAEs (occurring in > 15.0% of patients) were asthenia (25.5%), fatigue (21.1%), dyspnea (21.1%), pyrexia (19.6%), diarrhea (19.1%), anemia (18.6%), nausea (17.6%), decreased appetite (17.6%), cough (17.2%), and back pain (15.7%). Approximately two-thirds of patients (67.2%) experienced TEAEs deemed possibly treatment related (Table 2). Serious treatment-related TEAEs occurred in 10.8% of patients and grade ≥ 3 treatment-related TEAEs occurred in 13.7%.

Twenty-one patients (10.3%) died within 30 days of their last cetrelimab dose. For 17 patients, the primary cause of death was disease progression. AEs were the primary cause of death for four patients and one of those AEs (the DLT of myasthenia gravis) was considered treatment related. Dyspnea was the cause of death in two patients and acute heart failure in one patient. Fifteen patients (7.4%) experienced TEAEs leading to death.

The safety profile at the RP2D (240 mg Q2W IV) was similar to that in the overall all-treated population, with serious and grade ≥ 3 TEAEs that were considered treatment-related occurring in 12.3% and 14.8%, respectively. Treatment-related TEAEs at a dose of 240 mg Q2W resulted in

| Table 2  Summary of TEAEs (all-treated population) |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| 80 mg Q2W n = 4 | 240 mg Q2W n = 162 | 460 mg Q2W n = 4 | 480 mg Q4W n = 28 | 800 mg Q2W n = 6 | Total N = 204 |
| Any TEAEs, n (%) | Any TEAEs, n (%) | Any TEAEs, n (%) | Any TEAEs, n (%) | Any TEAEs, n (%) | Any TEAEs, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |
| Serious TEAEs, n (%) | Serious TEAEs, n (%) | Serious TEAEs, n (%) | Serious TEAEs, n (%) | Serious TEAEs, n (%) | Serious TEAEs, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |
| Grade ≥ 3 TEAEs, n (%) | Grade ≥ 3 TEAEs, n (%) | Grade ≥ 3 TEAEs, n (%) | Grade ≥ 3 TEAEs, n (%) | Grade ≥ 3 TEAEs, n (%) | Grade ≥ 3 TEAEs, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |
| TEAEs leading to treatment interruption, n (%) | TEAEs leading to treatment interruption, n (%) | TEAEs leading to treatment interruption, n (%) | TEAEs leading to treatment interruption, n (%) | TEAEs leading to treatment interruption, n (%) | TEAEs leading to treatment interruption, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |
| TEAEs leading to dose reduction, n (%) | TEAEs leading to dose reduction, n (%) | TEAEs leading to dose reduction, n (%) | TEAEs leading to dose reduction, n (%) | TEAEs leading to dose reduction, n (%) | TEAEs leading to dose reduction, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |
| TEAEs leading to withdrawal, n (%) | TEAEs leading to withdrawal, n (%) | TEAEs leading to withdrawal, n (%) | TEAEs leading to withdrawal, n (%) | TEAEs leading to withdrawal, n (%) | TEAEs leading to withdrawal, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |
| TEAEs leading to death, n (%) | TEAEs leading to death, n (%) | TEAEs leading to death, n (%) | TEAEs leading to death, n (%) | TEAEs leading to death, n (%) | TEAEs leading to death, n (%) |
| Treatment related | Treatment related | Treatment related | Treatment related | Treatment related | Treatment related |

Patients with > 1 record are counted only once at corresponding rows
Q2W every 2 weeks, Q4W every 4 weeks, TEAE treatment-emergent adverse event
dose interruptions in 29.0% of patients and discontinuation in 6.8%.

**AEs of clinical interest**

Immune-related AEs were reported by the investigator for 35.3% of patients (72/204). The most common irAEs were hypothyroidism (6.9%), asthenia (4.4%), diarrhea (3.4%; assumed to be immune related based on response to empirical steroid treatment), rash (2.9%), hyperthyroidism (2.9%), dyspnea (2.9%), pruritus (2.5%), and pneumonitis (2.5%). Grade ≥ 3 irAEs were reported for 6.9% of patients (14/204). Pneumonitis was the only grade ≥ 3 treatment-emergent irAE that occurred in two patients (1.0%); all other grade ≥ 3 irAEs occurred in a single patient (0.5%). One patient receiving 240 mg Q2W experienced serious autoimmune colitis and discontinued study treatment.

IRRs were reported for 14.2% of patients (29/204). Median time to onset of first IRR was 15 (range, 1–148) days and median time to resolution of first IRR was 1 (range, 1–5) day. The majority of IRRs occurred after the first two doses. Two patients (1.0%) experienced grade ≥ 3 IRRs and one patient discontinued study treatment due to a grade 3 IRR of hypertension.

**Pharmacokinetics**

The pharmacokinetics of cetrelimab were linear and dose proportional across IV doses of 80, 240, 460, and 800 mg Q2W, with moderate variability after the first dose (Fig. 2a and Online Resource 1). The shape of the serum concentration–time profile was similar for all patients receiving cetrelimab 480 mg IV Q4W regardless of whether the drug product had been formulated as frozen liquid or lyophilized (Online Resource 2). Data from patients receiving 480 mg Q4W IV were pooled and analyzed (Online Resource 1). Pharmacokinetic exposures [\(C_{\text{max}}\), trough concentration (\(C_{\text{trough}}\)], AUC over a dosing interval (\(\tau\)) (AUC\(\tau\)) increased after each repeated IV dose until steady state appeared to be reached after four doses with the Q4W schedule and seven doses with the Q2W schedule (Fig. 2b). After multiple IV doses of 240 mg Q2W and 480 mg Q4W cetrelimab, the steady-state accumulation ratios for these pharmacokinetic exposures were approximately 2.0- to 3.5-fold (Online Resource 3 and Online Resource 4).

The mean \(C_{\text{trough}}\) of 240 mg Q2W (66.9 µg/mL) was higher than the mean \(C_{\text{trough}}\) of 480 mg Q4W (48.2 µg/mL). The \(t_{1/2}\) calculated from NCA of steady-state pharmacokinetic data from the 480 mg Q4W groups (22.4 days) was consistent with the predicted \(t_{1/2}\) via popPK modeling (25.0 days). At Dose 9 of 240 mg Q2W during phase 2, the mean accumulation ratios of the \(C_{\text{trough}}\) and \(C_{\text{max}}\) were 2.86 and 1.84, respectively (\(n = 68\)). Both mean accumulation ratios were similar to those observed for 240 mg Q2W in phase 1 (3.29 and 2.05, respectively; \(n = 3\)).

Body weight and albumin were identified as two of the significant covariates for CL and body weight was identified as a significant covariate for V1 (data on file).

**Immunogenicity**

The overall prevalence of anti-cetrelimab antibodies was 1.7% (3/182 patients with available data); 2.2% of patients in the phase 2 part of the study who were treated with IV cetrelimab 240 mg Q2W developed anti-cetrelimab antibodies (3/134 patients with available data). Anti-cetrelimab antibodies did not appear to affect cetrelimab pharmacokinetics (Online Resource 5).

**Pharmacodynamics**

**Biomarker expression**

In the all-treated population, IP10 concentration was significantly increased \((P = 0.012)\) over baseline on Day 43 (Online Resource 6). Significant elevation of IL2Ra chain was observed on Day 43 in patients with stable disease \((P = 0.0006)\) and progressive disease \((P < 0.0001)\), but not in patients with CR or PR following treatment with 240 mg Q2W cetrelimab.

**Receptor occupancy**

PD-1 RO saturation was achieved at the first time point when RO samples were collected, 2 h post-EOI. Similar levels of PD-1 RO saturation on CD3+ T cells were observed across all dose levels throughout treatment and at the EOT visit after cetrelimab discontinuation (Fig. 3a).

**Ex vivo pharmacodynamics modulation**

Cetrelimab treatment induced maximum IL-2 expression (stimulation ratio = 1) across all doses (240 mg Q2W, 480 mg Q4W, 800 mg Q2W) tested (Fig. 3b), indicating that maximal inhibitory activity of PD-1 was achieved and maintained throughout the dosing period across all doses, extending to 30 days after cessation of cetrelimab treatment.

**Efficacy**

In the all-treated population from both phases of LUC1001, the ORR was 18.6% (38/204) and the CBR was 31.3% (64/204). Six patients (2.9%) had CR, 32 (15.7%) had PR, and 36 (17.7%) had stable disease. Median PFS was 2.8 (95% CI 1.9–3.7) months and median OS was 17.8 (95% CI
11.9–22.6) months (Online Resource 7 and Online Resource 8).

Non-small-cell lung cancer cohort

Of 35 patients with NSCLC in phase 1 and phase 2 included in the clinical analysis, 71.4% were diagnosed with adenocarcinoma, 22.9% with squamous cell carcinoma, 1 with large-cell carcinoma, and 1 with “other.” At screening, 94.3% of patients had stage IV NSCLC, and 97.1% had previously received chemotherapy. Mutation status was known for 15 patients (42.9%): a \textit{KRAS} mutation was identified in 3 patients (8.6%), an \textit{EGFR} mutation in 3 (8.6%), and other mutations in 9 (25.7%). Nineteen patients (54.3%) expressed high levels of PD-L1 and would have been eligible to receive PD-1 inhibitor therapy in clinical practice.

The median follow-up was 15.7 (range, 0.3–25.4) months. In all 35 patients, the ORR was 34.3% and the CBR was

---

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig2}
\caption{Mean (± SD) serum concentration–time curves \textit{a} after the first cetrelimab dose, \textit{b} after repeated cetrelimab doses. * Frozen and lyophilized drug product pooled}
\end{figure}
Fig. 3 Pharmacodynamic effects of cetrelimab. a Mean (± SD) of PD-1 receptor occupancy over time. PD-1 receptor occupancy was measured by percent molecules of equivalent soluble fluorochrome (MESF) CD3⁺ in plasma by visit and dose level in the receptor occupancy analysis set. PD-1 receptor occupancy increased to 100% at all IV dose levels studied within 2 h post dose and remained at saturation at all time points during multiple doses. b Ratio of staphylococcal enterotoxin B (SEB)–stimulated interleukin-2 production in peripheral blood mononuclear cells treated with isotype versus cetrelimab. EOI end of infusion, EOT end of treatment, IV intravenous, PD-1 programmed cell death protein-1, Pre predose, Q2W every 2 weeks, Q4W every 4 weeks.
51.4%. In the subgroup of 19 patients with PD-L1-high (≥ 50% PD-L1+) tumors, the ORR was 52.6% and the CBR was 73.7%. The overall median duration of treatment was 7.0 (range, 0.0–24.7) months for all treated patients and longer [10.7 (range, 1.0–24.7) months] among patients with PD-L1 high tumors. Median DOR could not be estimated, because there was an insufficient number of progression events at data cutoff. For all treated patients, median PFS was 7.4 [95% CI 2.43–not estimable (NE)] months and the median OS was 22.4 (95% CI 9.95–NE) months (Online Resource 7 and Online Resource 8). Response and duration of treatment for individual patients are shown in Online Resource 9 and Fig. 4.

Melanoma cohort

Fifty patients with melanoma enrolled in phase 1 and phase 2 combined, including six with uveal melanoma. Of these, 37 (74.0%) had previously received systemic treatment. Prior treatments included ipilimumab (38.0%), BRAF/MEK-targeted therapy (26.0%), IFN (24.0%), and chemotherapy (36.0%). All patients had stage IV melanoma at screening except one patient (2.0%) with stage III. BRAF mutations were found in 19 patients (45.2%) and PD-L1 status was positive (> 1%) for 8 (16.0%) patients. The median duration of follow-up for all patients was 16.6 (range, 0.7–25.1) months. The overall median duration of treatment was 5.5 (range, 0.0–25.0) months for all treated patients.

In all 50 patients, the ORR was 28.0% and the CBR was 46.0%. The six patients with uveal melanoma had progression as best response. Among the eight patients who were PD-L1+ (PD-L1 IHC ≥ 1%), the ORR was 50.0% and the CBR was 75.0%. Median DOR and OS could not be estimated (Online Resource 7). The median PFS for all treated patients was 5.4 (95% CI 2.73–9.95) months (Online Resource 8). Response and duration of treatment for individual patients are shown in Online Resource 10 and Fig. 4.

MSI-H/dMMR CRC cohort

Of 48 patients with CRC enrolled in phase 1 and 2, 21 were centrally determined to be MSI-H by IHC. Twelve patients were normal (microsatellite stable) by central laboratory and nine could not be evaluated by the central laboratory. At screening, all patients with CRC had stage IV disease, and all had received prior systemic therapy; 46 patients (95.8%) received chemotherapy and one (2.1%) received BRAF/MEK-targeted therapy.

Patients with MSI-H CRC had a median treatment duration of 9.9 (range, 0.0–16.1) months, while the all-treated CRC population had a median treatment duration of 2.4 (range, 0.0–19.9) months. The median follow-up was 12.1 (range, 0.3–24.3) months for the all-treated population and 12.3 (range, 0.9–16.3) months for those with MSI-H CRC.

In all 48 patients with CRC, the ORR was 16.7% and the CBR was 73.7%. The overall median duration of treatment was 2.4 (range, 0.0–25.0) months for all treated patients.

Discussion

In this first-in-human, phase 1/2 study, the safety, pharmacokinetics, pharmacodynamics, and biomarkers of cetrelimab were thoroughly characterized in PD-1/PD-L1 inhibitor–naïve patients with advanced or refractory solid tumors. Detailed characterization of cetrelimab monotherapy is essential for the selection of dosing regimens to accommodate potential schedules of combination partners. In phase 1 of LUC1001, cetrelimab was well tolerated across the IV doses of 80, 240, 460, or 800 mg Q2W or 480 mg Q4W. The safety profile of cetrelimab was consistent with that of other anti-PD-1 antibodies. As expected with immune checkpoint inhibitors, immune-related AEs were observed and they were managed with corticosteroids and treatment interruption. Only two DLTs occurred during the dose-escalation phase. Across phases 1 and 2, although 137 patients (67.2%) experienced TEAEs deemed possibly treatment related, most were managed by dose interruption, and only 12 patients (5.9%) experienced treatment-related AEs resulting in treatment discontinuation. No unexpected safety signals were observed. The prevalence of IRRs was higher for cetrelimab (14.2%), as reported by the investigators, compared with that reported for pembrolizumab (0.2%) and nivolumab (6.4%) [24–26]. Notably, the majority of cetrelimab IRRs were grade 1–2 and occurred after the first two doses. Other studies with cetrelimab using the lyophilized formulation have not reported high frequencies of IRRs [27].

Serum cetrelimab steady-state C_{trough} for IV doses of cetrelimab 240 mg Q2W (66.9 µg/mL) and 480 mg Q4W (48.2 µg/mL) derived from the simulations, based on the popPK model parameters and associated interpatient variability, were similar and in range with other PD-1 inhibitors such as nivolumab [28–30] (56.5 µg/mL) and pembrolizumab [31–33] (23.3 µg/mL) at their respective approved clinical doses. The two cetrelimab regimens achieved the
same total dose exposure, while demonstrating acceptable safety and sufficient pharmacokinetics/pharmacodynamics coverage to ensure RO saturation throughout the dosing interval. Furthermore, the clearance of cetrelimab at steady state (8.6 mL/h in the 240 mg IV Q2W group, 9.8 mL/h in the 480 mg IV Q4W group) was similar and in range with that of nivolumab [30] (9.5 mL/h) and pembrolizumab [33] (9.2 mL/h) at their respective approved clinical doses.

**Fig. 4** Efficacy measures in patients with a, b NSCLC (total and PD-L1 ≥ 50%), c, d melanoma (total and PD-L1 ≥ 1%), and e, f MSI-H/dMMR CRC (total and MSI-H). ORR is defined as the percentage of all treated patients with CR or PR. CBR is defined as the percentage of all treated patients with CR, PR, or SD (≥ 24 weeks after first study drug). CBR clinical benefit rate, CI confidence interval, CR complete response, CRC colorectal cancer, dMMR DNA mismatch repair deficient, MEL melanoma, MSI-H microsatellite instability–high, NSCLC non-small-cell lung cancer, ORR overall response rate, PD progressive disease, PD-L1 programmed death ligand 1, PR partial response, SD stable disease.
The median \( t_{1/2} \) of cetrelimab was aligned between NCA (22.4 days) and the popPK model (25.0 days) and conforms to the expected behavior of enhanced neonatal FC receptor–mediated recycling for IgG antibodies at around 3 weeks [34]. The reported terminal \( t_{1/2} \) was 25 days for nivolumab [28] and in the range of 14–22 days for pembrolizumab [35]. Based on the totality of safety, pharmacokinetics, pharmacodynamics, biomarkers, and efficacy data, the RP2D for cetrelimab may be 240 mg Q2W or 480 mg Q4W. The different dosing intervals provide flexibility in coordinating combination treatment; patients only received 240 mg Q2W in the phase 2 study to minimize sample size.

A relatively flat dose–response relationship has been demonstrated for two approved PD-1 inhibitors (nivolumab and pembrolizumab), suggesting a relatively broad therapeutic window (around 1–10 mg/kg) for the anti-PD-1 mechanism of action [28, 36, 37]. Nivolumab 480 mg Q4W was shown to be equivalent in clinical safety and efficacy to its previously approved 240 mg Q2W dosing schedule and has been approved as an alternate dosing schedule for most oncology indications in the United States [1, 24, 38]. For pembrolizumab, based on exposure–response modeling, the dosing interval has been extended to 400 mg Q6W [39] and longer dosing intervals may also be considered [25].

Anti-cetrelimab antibodies were detected in a small proportion of patients in phase 1 (1.7%) and phase 2 (2.2%) and did not appear to affect the pharmacokinetics of cetrelimab. Therefore, available data suggest that anti-cetrelimab antibodies do not impact clinical activity.

Preliminary efficacy data reported suggest that the efficacy profile of cetrelimab may be consistent with known profiles of PD-1 inhibitors in melanoma [40–45], PD-L1-high NSCLC [7, 11, 46–49], and MSI-H CRC [14, 15, 50]. Focusing on these tumor types allowed for a better point estimate on the response rate to be observed with cetrelimab in the sample sizes selected for this study. Compared with all treated patients, ORRs were high in subgroups with tumors carrying predictive biomarkers. This study supports existing evidence that suggests MSI testing is highly variable and should be standardized to improve the reliability of determining MSI-H among patients with CRC [51].

In summary, the phase 1/2 LUC1001 study characterized the safety, pharmacokinetics, pharmacodynamics, and efficacy data of cetrelimab in patients for the first time to support cetrelimab dose schedules of IV 240 mg Q2W and 480 mg Q4W. It is important to acknowledge that multiple PD-1 agents have already been approved for the treatment of PD-1/PD-L1 inhibitor–naïve patients with advanced or refractory solid tumors; cetrelimab is currently being developed to support combination studies that are ongoing. Furthermore, data from the phase 1/2 LUC1001 study cannot be directly compared with those from other trials at this time due to the small sample size and study design that is not controlled with an active comparator. The data reported here are critical for understanding cetrelimab in a clinical setting, and these findings are consistent with results with other approved PD-1 inhibitors. Based on the preliminary antitumor activity of cetrelimab in patients with advanced solid tumors in LUC1001 [52], studies are ongoing to evaluate the safety and efficacy of cetrelimab in combination with intravesical gemcitabine (TAR-200; JNJ-17000139-AAC) in non-muscle-invasive bladder cancer (NCT04640623) and in combination with erdafitinib in patients with urothelial carcinoma carrying FGFR alterations (NCT03473743), as chemotherapy or targeted therapy can release tumor neoantigens and prime the tumor microenvironment for immune response by a PD-1 inhibitor. These studies, however, are required to determine the safety and efficacy of such combinations based on the unpredictability in treating cancer and delivering meaningful new treatment options to patients.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00280-022-04414-6.

**Acknowledgements** This work was supported by Janssen Research & Development. Writing assistance was provided by Ann C. Sherwood, PhD, of Janssen; and by Sarika Sharma, PhD, Russell Craddock, PhD, and Benjamin Ricca, PhD, of Parexel. Writing assistance was funded by Janssen Research and Development.

**Funding** This study was funded by Janssen Research & Development.

**Declarations**

**Conflict of interest** Enriqueeta Felip declares advisory board participation for AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Blue Print Medicine, Boehringer Ingelheim, BMS, Lilly, GSK, Janssen, Medical Trends, Merck KGaA, Merck Sharp and Dohme, Novartis, Pembrotyc, Pfizer, Puma Biotechnology, Regeneron, Roche, Sanofi Genzyme, Syneos Health, Takeda, Grifols; speaker bureau participation for AstraZeneca, Boehringer Ingelheim, BMS, Lilly, Merck Sharp and Dohme, Novartis, Peervoice, Pfizer, prIME Oncology, Roche, Takeda, Touchmedical, CME Outfitters; research funding from Fundación Merck Salud and a grant for oncology innovation; and is an Independent Member of the Board at Grifols. Victor Moreno declares consulting fees from Basilea, Bayer, BMS, Roche, and Janssen; and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, BMS, and Janssen. Daniel Morgenstern declares consulting fees from AbbVie, Gilead, Ol 1 Therapeutics, Lilly, PharmaMar, and Takeda; and participation on a data safety and monitoring board or advisory board for BMS. Giuseppe Curigliano declares personal fees from AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Foundation Medicine, GSK, Lilly, Novartis, Pfizer, Roche, Samsung, and Seagen; non-financial support from Pfizer and Roche; grants from Merck; and other conflicts of interest/competing interests outside the submitted work from Ellipsis. Piotr Rutkowski declares payment or honoraria from BMS, Merck, MSD, Novartis, Pierre Fabre, and Sanofi; and participation on a data safety monitoring board or advisory board for Blueprint Medicines, BMS, Merck, MSD, Philogen, Pierre Fabre, and Sanofi. Diego Cortinovis declares speaker bureau participation for AstraZeneca, BMS, Boehringer Ingelheim, and MSD; and consultancy fees for Amgen, Novartis, and Roche. Ruth Plummer declares institutional grants for clinical trial costs from...
Janssen. Michele Maio declares consulting fees, travel reimbursement, participation in a data safety monitoring board or advisory board, and honoraria from Alfasigma, Amgen, AstraZeneca, BMS, GSK, Incyte, Lilly, Merck, MSD (consulting fees only), Pierre-Fabre, Roche, Sanofi, and Sciclone; and owns stocks or stock options from Epigen Therapeutics and Theravance. Paolo A. Ascieto declares consulting fees from 4SC, AstraZeneca, BMS, Boehringer-Ingelheim, Daiichi, Eisai, Idera, Immunocore, Italfarmaco, iTeos, Luminaphore, Merck Serono, Merck Sharpe and Dohme, Nektar, Nouscom, Novartis, Oncosec, Pfizer, Pierre-Fabre, Regeneron, Roche/Genentech, Sandoz, Sanayko, Sanofi, Seagen, and Sun Pharma; and institutional grants from BMS, Pfizer, Roche/Genentech, and Sanofi. Enrique Zudaire, Anasuya Hazra, Huy-Seagen, and Sun Pharma; and institutional grants from BMS, Pfizer, Pierre-Fabre, Regeneron, Roche/Genentech, Sandoz, Sanayko, Sanofi, Seagen, and Sun Pharma; and institutional grants from BMS, Pfizer, Roche/Genentech, and Sanofi. Enrique Zudaire, Anasuya Hazra, Huy-Scar Sankjo, Sanofi, Sharpe and Dohme, Nektar, Nouscom, Novartis, Oncosec, Pfizer, Immunocore, Italfarmaco, iTeos, Luminaphore, Merck Serono, Merck 4SC, AstraZeneca, BMS, Boehringer-Ingelheim, Daiichi, Eisai, Idera, Immunocore, Italfarmaco, iTeos, Luminaphore, Merck Serono, Merck Sharpe and Dohme, Nektar, Nouscom, Novartis, Oncosec, Pfizer, Pierre-Fabre, Regeneron, Roche/Genentech, Sandoz, Sanayko, Sanofi, Seagen, and Sun Pharma; and institutional grants from BMS, Pfizer, Roche/Genentech, and Sanofi. Enrique Zudaire, Anasuya Hazra, Huy-brecht T’jollyn, James G. Greger, Edward Attiyeh, Nibedita Bandypadhyay, and Hong Xie are employees of Janssen and may own stocks or shares. Emiliano Calvo declares advisory board participation (fi-nancial interest) for Adcendo, Alkermes, Amunix, Anaveon, Amcure, AstraZeneca, BMS, Janssen, MontTa, MSD, Nanobioticx, Nouscom, Novartis, OncoDNA, PharmaMar, Roche/Genentech, Sanofi, Servier, SyneosHealth, TargImmune, and T-knife; research grants for Achil-les and BeiGene; steering committee (financial interest) and IDMC participation for BeiGene (IDMC steering committee), EORTC IDMC chair (non-financial interest), MedSIR (steering committee), and Novartis (steering committee); honoraria for scientific board participation for Adcendo, Chugai Pharmaceuticals, and PsiOxus Therapeutics; employment at HM Hospitals Group and START Program of Early Phase Clinical Drug Development in Oncology, START corporation, Oncoret Associated, and International Cancer Consultants; and is the founder and president of the not-for-profit Investigational Therapeutics in Oncological Sciences (INTHEOS) Foundation. Aitana Calvo, And-res Cervantes, Dariusz Kowalski, José Manuel Trigo, and Vladimir I. Vladimirov have no relevant disclosures to disclose.

Ethical approval The study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Stan-dards and the principles set forth in the Declaration of Helsinki. The pro-tocol was approved by institutional and ethics committees at each site.

Consent to participate All participants provided written informed con-sent before participation in the study.

Consent for publication Not applicable.

Availability of data and materials Janssen Pharmaceutical Companies of Johnson & Johnson’s data sharing policy is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for study data access can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

Open Access This article is licensed under a Creative Commons At-tribution 4.0 International License, which permits use, sharing, adapta-tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Guerrouahen BS, Maccalli C, Cugno C, Rutella S, Akporiaye ET (2019) Reverting immune suppression to enhance cancer immuno-therapy. Front Oncol 9:1554. https://doi.org/10.3389/fonc.2019.01554
2. Reiss KA, Forde PM, Brahmer JR (2014) Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy 6:459–475. https://doi.org/10.2217/imt.14.9
3. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC (2001) Structural basis for co-stimulation by the human CTLA-4/ B7-2 complex. Nature 410:604–608. https://doi.org/10.1038/ 35069112
4. Zhang X, Schwartz JC, Nathenson SG, Almo SC (2001) Crystalization and preliminary X-ray analysis of the complex between human CTLA-4 and B7-2. Acta Crystallogr D Biol Crystallogr 57:898–899. https://doi.org/10.1107/s0907444901005777
5. Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008) Crystal structure of the complex between pro-grammed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci USA 105:10483–10488. https://doi.org/10.1073/pnas.080443 5105
6. Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malm-strom PU, Tottermann TH (2005) Optimization of the MB49 mouse bladder cancer model for adenosine receptor therapy. Lab Anim 39:384–393. https://doi.org/10.1258/00236770577428475
7. Ready NE, Olt PA, Hellmann MD, Zuzagagoitia J, Hann CL, de Braud F et al (2020) Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol 15:426–435. https://doi.org/10.1016/j.jtoho.2019.10.004
8. European Medicines Agency (2019) Libtayo (cemiplimab) European public assessment report. https://www.ema.europa.eu/en/ medicines/human/EPAR/libtayo. Accessed 10 Mar 2021
9. Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529. https://doi.org/10.1136/bmj.k3529
10. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K (2018) Bio-markers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 17:129. https://doi.org/10.1186/s12943-018-0864-3
11. Hui R, Garon EB, Goldman JW, Leigh NB, Hellmann MD, Pat-naik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA (2017) Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol 28:874–881. https://doi.org/10.1093/annonc/ mdx008
12. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413. https://doi.org/10.1126/science.aan6733
13. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520. https://doi.org/10.1056/ NEJMoa1500596
14. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773–779. https://doi.org/10.1200/JCO.2017.76.9901
15. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelsson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinite GA, Kopetz S, Andre T
(2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182–1191. https://doi.org/10.1016/S1470-2045(17)30422-9

16. DeAngelis N, Ferrante C, Powers G, Sendecki J, Mattson B, Pizutti D, Packman K, Wang W, Trouba K, Nanjunda R, Lacy ER, Wheeler J, Britttingham R, Wu SJ, Luo J, Lorenzi MV, Verona RI (2022) Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody in human cancer models. Cancer Chemother Pharmacol (in press)

17. European Medicines Agency (2015) Keytruda (pembrolizumab) European public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda. Accessed 10 Mar 2021

18. Fessas P, Lee H, Ikemizu S, Janowitz T (2017) A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol 44:136–140. https://doi.org/10.1053/j.seminoncol.2017.06.002

19. European Medicines Agency (2015) Opdivo (nivolumab) European public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo. Accessed 10 Mar 2021

20. Wang C, Thudium KB, Han M, Wang X-T, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846–856.

21. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elssass-Schaap J, Beeram M et al (2015) Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293. https://doi.org/10.1185/1078-0432.CCR-14-2607

22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

23. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA (2018) Trial Reporting in Immuno-Oncology (TRIO): an American Society of Clinical Oncology-Society for Immunotherapy of Cancer statement. J Immunother Cancer 6:108. https://doi.org/10.1186/s40425-018-0426-7

24. Bristol Myers Squibb. Opdivo (nivolumab) [prescribing information]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554Orig1s000ClinPharmR.pdf. Accessed 10 Mar 2021

25. Center for Drug Evaluation and Research (2014) Clinical pharmacology and biopharmaceutics review(s): Opdivo (nivolumab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000ClinPharmR.pdf. Accessed 10 Mar 2021

26. Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX (2017) Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8:730. https://doi.org/10.3389/fphar.2017.00730

27. Moreno V, Loriot Y, Rutkowski P, Beato C, Felip E, Duran I et al (2020) Evolving development of PD-1 therapy: cetrelimab (JNJ-63723283) from monotherapy to combination with eraditinib. J Clin Oncol 38:3055

28. Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol 6:58–66. https://doi.org/10.1002/psp4.12143

29. Brahmer JR, Laczetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino J et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6389

30. Center for Drug Evaluation and Research (2014) Clinical pharmacology and biopharmaceutics review(s): Opdivo (nivolumab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000ClinPharmR.pdf. Accessed 10 Mar 2021

31. Brahmer JR, Laczetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino J et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6389

32. Ahmadia M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, Elssass-Schaap J, Kondic A, Stone J (2017) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 6:49–57. https://doi.org/10.1002/psp4.12139

33. Brahmer JR, Laczetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino J et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6389

34. Andersen JT, Dalhus B, Vuijf D, Ravn BT, Gunnarsen KS, Pfamridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjoras M, Jkeaufi L, Steep D, Sandile I, Cameron J (2014) Extending serum half-life of albumin by engineering neotnal Fc receptor (FcRn) binding. J Biol Chem 289:13492–13502. https://doi.org/10.1074/jbc.M114.549832

35. Elssass-Schaap J, Rossenau S, Lindauer A, Kang SP, de Greef R, Sachs JR, de Alwis DP (2017) Using model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 Trial. CPT Pharmacometrics Syst Pharmacol 6:21–28. https://doi.org/10.1002/psp4.12132

36. Wang X, Feng Y, Bajaj G, Gupta M, Agrawal S, Yang A, Park JS, Lestini B, Roy A (2017) Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacometrics Syst Pharmacol 6:40–48. https://doi.org/10.1002/psp4.12133

37. Ahmed A, Turner D, Felip E, Lena H, Cappuzzo F, Horn L, Garon E, Hui R, Arkenau H-T, Hubens M (2016) Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 27:1291–1298

38. Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X (2018) Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 29:2208–2213. https://doi.org/10.1093/annonc/mdy408

39. Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L (2020) A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 131:68–75

40. D’Angelo SP, Larkin J, Somasan JA, Lebbe C, Brady B, Neyes B et al (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35:226–235. https://doi.org/10.1200/JCO.2016.67.9258

41. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al (2018) Adjuvant pembrolizumab versus placebo
Authors and Affiliations

Enriqueta Felip\textsuperscript{1} · Victor Moreno\textsuperscript{2} · Daniel Morgensztern\textsuperscript{3} · Giuseppe Curigliano\textsuperscript{4} · Piotr Rutkowski\textsuperscript{5} · José Manuel Trigo\textsuperscript{6} · Aitana Calvo\textsuperscript{7} · Dariusz Kowalski\textsuperscript{5} · Diego Cortinovis\textsuperscript{8} · Ruth Plummer\textsuperscript{9} · Michele Maio\textsuperscript{10} · Paolo A. Ascierto\textsuperscript{11} · Vladimir I. Vladimirov\textsuperscript{12} · Andres Cervantes\textsuperscript{13} · Enrique Zudaire\textsuperscript{14} · Anasuya Hazra\textsuperscript{14} · Huybrecht T’jollyn\textsuperscript{15} · Nibedita Bandyopadhyay\textsuperscript{16} · James G. Greger\textsuperscript{14} · Edward Attiyeh\textsuperscript{14} · Hong Xie\textsuperscript{14} · Emiliano Calvo\textsuperscript{17}

\textsuperscript{1} Thoracic Cancer Unit, Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain
\textsuperscript{2} Phase 1 Trials Unit, START MADRID-FJD, Hospital Fundación Jiménez Díaz Medical Oncology Division, Madrid, Spain
\textsuperscript{3} Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA
\textsuperscript{4} Division of Early Drug Development, European Institute of Oncology, IRCCS and University of Milano, Milan, Italy
\textsuperscript{5} Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
\textsuperscript{6} Department of Medical Oncology, Hospital Universitario Virgen de La Victoria y Regional, Malaga, Spain
\textsuperscript{7} Oncology Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain
\textsuperscript{8} Oncology Unit, San Gerardo Hospital, Monza, Italy
\textsuperscript{9} Sir Bobby Robson Unit, Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle, UK
\textsuperscript{10} Center for Immuno-Oncology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
\textsuperscript{11} Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS–Fondazione Pascale, Napoli, Italy
\textsuperscript{12} Pyatigorsk Oncology Dispensary, Pyatigorsk, Russia
\textsuperscript{13} Medical Oncology Department, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
\textsuperscript{14} Janssen Research & Development, Spring House, PA, USA
15 Janssen Research & Development, Beerse, Belgium
16 Janssen Research & Development, Raritan, NJ, USA
17 Centro Integral Oncológico Clara Campal Medical Oncology Division, START Madrid-CIOCC, Sanchinarro University Hospital, Madrid, Spain